Spravato billing is one of the most complex reimbursement challenges in behavioral health today. Unlike standard psychiatric medications, Spravato (esketamine) requires REMS program certification, in-office administration under direct supervision, 2-hour post-administration patient monitoring, and precise multi-code claim submission, all before a single dollar is reimbursed. According to the FDA, Spravato is available only through a restricted distribution program called the Spravato REMS, due to the risks of sedation, dissociation, and respiratory depression associated with its administration. For providers, getting billing right is not optional. It is a prerequisite to getting paid.
What Makes Spravato Billing Different From Standard Psychiatric Billing
Spravato billing is fundamentally different from standard psychiatric billing because every session requires REMS compliance, real-time monitoring documentation, and multi-code claim submission bundled into a single date of service. Standard psychiatric billing typically involves a single evaluation and management code. Spravato billing requires providers to accurately capture the drug, administration, supervision, and observation as separate or bundled billable components, depending on the payer.
This complexity is compounded by the fact that Spravato is a Schedule III controlled substance under the Controlled Substances Act, as confirmed by the FDA. Its restricted legal status means providers cannot treat it like a standard dispensed medication. Every administration must take place in a REMS-certified healthcare setting, and every session must be meticulously documented to support the claim.
The REMS Program and Why It Changes Everything for Billing
The Spravato REMS program changes billing because non-compliance with its requirements directly results in claim denials, payment delays, and potential post-payment audits. According to the FDA, the Spravato REMS requires 4 levels of certification and enrollment before treatment can begin: the healthcare setting must be certified, the pharmacy must be certified, the prescribing provider must be enrolled, and the patient must be enrolled in the REMS program prior to receiving treatment in an outpatient setting.
Beyond enrollment, the REMS mandates that providers have a healthcare provider onsite to monitor each patient for at least 2 hours following administration, tracking sedation, dissociation, respiratory depression, and changes in heart rate, blood pressure, and respiratory status. According to the FDA, a Patient Monitoring Form must be completed and submitted for every patient within 7 days following administration. Failure to submit this form is a REMS violation that can trigger an audit and jeopardize reimbursement.
Spravato must never be dispensed directly to a patient for home use. Any claim submitted without documented in-office administration and monitoring will be denied.
Spravato Billing Requirements Providers Must Meet Before Submitting a Claim
Providers must meet 3 minimum requirements before submitting a Spravato claim: confirmed REMS certification, documented in-office administration, and verified prior authorization from the patient’s payer. According to the FDA, all records of Spravato shipments received and dispensing information, including the patient name, must be maintained by the certified healthcare setting. These records are subject to audit and must be readily available.
Providers must also confirm the patient’s coverage pathway before billing. Spravato can be covered under a patient’s medical benefit or pharmacy benefit, depending on the payer and the billing arrangement. Submitting a claim to the wrong benefit line is one of the leading causes of Spravato claim denials.
Spravato Billing Codes, Documentation, and Reimbursement Explained
Spravato billing uses a distinct set of HCPCS codes that differ by payer type, dose administered, and site of service, and selecting the wrong code is the single most common reason Spravato claims are denied. According to CMS’s Billing and Coding Article for Esketamine (A59249), the correct code depends on whether the patient is a Medicare beneficiary or covered under a commercial plan, and on the total dose administered per session.
HCPCS and CPT Codes Used for Spravato Billing
Spravato is billed using 3 primary HCPCS codes: G2082, G2083, and J0013, with code selection determined by dose and payer type. According to CMS:
- G2082 covers office or outpatient visits requiring physician supervision and administration of up to 56 mg of esketamine, including 2 hours of post-administration observation. This code is required for Medicare Part B claims at the 56 mg dose.
- G2083 covers the same service for doses greater than 56 mg, including the 84 mg dose. This code is also required for Medicare Part B claims at the higher dose.
- J0013 is the HCPCS code effective January 1, 2026, replacing the discontinued S0013 code for non-Medicare payers. J0013 is billed per 1 mg of esketamine administered. For a 56 mg dose, providers bill 56 units. For an 84 mg dose, providers bill 84 units.
Note that neither CPT code 99417 nor G2212 may be reported on the same date of service as the Spravato G codes, G2082 and G2083.
For diagnosis coding, CMS confirms that ICD-10-CM codes F32.5 and F33.42, which reflect major depressive disorder in full remission, are appropriate only for the maintenance phase of treatment. They are not appropriate for the induction phase.
Prior Authorization and Medical Necessity Documentation Requirements
Prior authorization is required by most payers before Spravato treatment begins, and initial approval is typically granted for 6 months, with annual renewal thereafter. According to published prior authorization policies aligned with CMS coverage guidance, providers must submit documentation that includes the patient’s diagnosis, prior treatment history showing failure of at least 2 antidepressant therapies, and confirmation that the prescribing provider is a mental health specialist such as a psychiatrist or nurse practitioner with a behavioral health specialty.
According to CMS’s Billing and Coding Article for Esketamine, all documentation must be maintained in the patient’s medical record and made available to the contractor upon request. This includes session-level notes that capture the dose administered, supervision provided, monitoring observations, start and end times, and the patient’s response to treatment.
Frequency of administration exceeding the FDA label is subject to medical review by CMS. The FDA-approved maximum is 8 administrations in month 1, 4 in month 2, and 4 per month from month 3 onward.
Conclusion
Spravato billing demands a level of precision that standard psychiatric billing workflows are not built to handle. From REMS certification and prior authorization to multi-code claim submission and dose-specific HCPCS selection, every step in the process has a direct impact on whether your practice gets paid accurately and on time. Providers who build the right internal systems get reimbursed. Providers who do not face denials, audits, and delayed revenue.
Spravato billing should not slow down your practice or your patients’ access to care. Our team specializes in esketamine billing services built around REMS compliance, payer-specific coding, and clean claim submission from day one. Contact us today to learn how we can take Spravato billing off your plate entirely.
FAQs
What billing codes are used for Spravato?
Spravato is billed using G2082 for doses up to 56 mg and G2083 for doses above 56 mg for Medicare, and J0013 for non-Medicare payers, effective January 1, 2026. Code selection depends on the dose administered and the patient’s insurance type.
Does Spravato require prior authorization?
Spravato requires prior authorization from most payers before the first session. According to CMS-aligned coverage policies, initial authorization is valid for 6 months and must be renewed annually for continued treatment.
Why are Spravato claims commonly denied?
Spravato claims are most commonly denied due to incorrect HCPCS code selection, missing monitoring documentation, and billing to the wrong benefit line. Each of these errors can be prevented with payer-specific verification and standardized session documentation.
What is the Spravato REMS program?
The Spravato REMS is an FDA-mandated restricted distribution program that requires healthcare settings, pharmacies, and patients to be certified or enrolled before Spravato can be administered or dispensed. Non-compliance with REMS requirements directly affects billing eligibility and reimbursement.